department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

relatlimab · pharmadog

pharmadog
drugs
relatlimab

drug · antibody

patient view →

relatlimab

Phase 2updated 2mo ago

by Bristol-Myers Squibb Co🔗 ChEMBL

Phase 2

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with an approval for melanoma and 13 investigational indications.

indications

indications

NSCLCColorectal CancerDLBCL

targets

Lymphocyte activation gene 3 protein

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

trade names

Relatlimab component of bms-986213, Relatlimab component of opdualag -rmbw

generic

relatlimab

MOA

Lymphocyte activation gene 3 protein inhibitor

indication

Metastatic Hepatocellular Carcinoma (HCC)

phase

phase_2

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 50m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 6

companyBristol-Myers Squibb Co2 co-mentions · 1 sources
tagRecall1 co-mentions · 1 sources
drugOPDIVO1 co-mentions · 1 sources
drugOPDIVO QVANTIG1 co-mentions · 1 sources
drugnivolumab1 co-mentions · 1 sources
drug(nivolumab + relatlimab)1 co-mentions · 1 sources

Trials studying relatlimab

phase2Pan Tumor Rollover Studyrecruitingn=1,500
phase2Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasisrecruitingn=15
phase2A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)completedn=468
phase1Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)active not recruitingn=31
phase3A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanomaactive not recruitingn=579
phase2A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)not yet recruitingn=260
phase2Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Canceractive not recruitingn=80
phase3A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanomarecruitingn=135

more trials →